Skip to content

Author

Min-Hu Chen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study.

BACKGROUND Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn's disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two year...

Min-Hu Chen, Ailsa L. Hart, A. Vadhariya et al. · 0 citations
Clinical trial Oct 2026

Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.

BACKGROUND Monoclonal antibodies targeting the interleukin-23 pathway are effective in treating inflammatory bowel disease. However, these therapies must be administered intravenously or by subcutaneous injection. METHODS We conducted a phase 2b, double-blind, randomized trial of oral icotrokinra, a peptide that bloc...

M. Abreu, B. Siegmund, L. Surace et al. · 0 citations
Review Open access Sep 2026

Case Report: Erdheim-Chester disease presenting as abdominal cocoon syndrome

Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm driven by MAPK pathway mutations. Although it frequently involves the bones, heart, and kidneys, initial manifestations predominantly affecting the gastrointestinal tract and mesentery are exceedingly rare, often leading to significant delays in clinical di...

Fang-Fang Liu, Meng Zhang, Fei Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.